证券代码：688639 证券简称：华恒生物 公告编号：2025-035 安徽华恒生物科技股份有限公司 第四届监事会第十八次会议决议公告 本公司监事会及全体监事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 一、监事会会议召开情况 安徽华恒生物科技股份有限公司（以下简称"公司"）第四届监事会第十八 次会议于 2025 年 9 月 4 日在公司会议室以现场结合通讯方式召开。本次会议应 到监事 3 人，实到监事 3 人。会议通知已于 2025 年 8 月 25 日以专人递送方式送 达全体监事。会议由监事会主席刘洋召集和主持。本次会议的召集、召开符合《中 华人民共和国公司法》和《公司章程》的有关规定。 二、监事会会议审议情况 经与会监事审议，议案表决结果如下： （一） 审议通过《关于公司发行 H 股股票并在香港联合交易所有限公司上 市的议案》 为深入推进公司全球化发展战略，提升品牌影响力与核心竞争力，巩固行业 领先地位，充分借助国际资本市场的资源与机制优势，优化资本结构，拓宽多元 融资渠道，全面提升公司治理水平和综合实力，公司拟发行境外上市外资股（H ...

Group 1 - The company plans to appoint RSM Hong Kong as the auditing firm for its H-share issuance and listing on the Hong Kong Stock Exchange, pending approval from the shareholders' meeting [1][2] - RSM Hong Kong was established on May 14, 2008, and is registered as a public interest entity auditor under the Hong Kong Accounting and Financial Reporting Ordinance, providing diverse services to clients [1][2] - The audit fees will be determined based on the company's business scale, work requirements, industry complexity, and the number of audit personnel involved, with management authorized to negotiate the final fees [2] Group 2 - The audit committee has reviewed and approved the appointment of RSM Hong Kong, confirming its professional capability and independence for the H-share issuance and listing [2] - The board of directors voted 9 in favor to appoint RSM Hong Kong as the auditing firm and to submit the proposal for shareholder approval [2] - The appointment of the auditing firm will take effect upon approval at the company's first extraordinary shareholders' meeting in 2025 [3]

Core Viewpoint - The company is moving forward with the issuance of H shares and plans to list on the Hong Kong Stock Exchange, which is seen as beneficial for its global development strategy and enhancing its international brand image [1][2]. Group 1: H Share Issuance and Listing - The independent directors unanimously support the proposal for the company to issue H shares and list on the Hong Kong Stock Exchange, believing it will aid in the company's global strategy and enhance its competitiveness [1]. - The proposed plan for the H share issuance complies with relevant laws and regulations, ensuring it does not harm the interests of the company or its shareholders [2]. - The fundraising plan associated with the H share issuance aligns with the company's development needs and global strategy, benefiting all shareholders [2]. Group 2: Profit Distribution and Insurance - The profit distribution plan prior to the H share issuance has been deemed fair to existing and future shareholders, with no adverse effects on their rights [2]. - The proposal to purchase liability insurance for directors and senior management is in accordance with legal requirements and market practices, ensuring no improper benefits are conferred [3]. - The independent directors support the hiring of a reputable auditing firm, which possesses the necessary experience and independence for the H share issuance project [3]. Group 3: Previous Fundraising Report - The report on the usage of previously raised funds has been reviewed and found to comply with regulatory requirements, accurately reflecting the company's financial activities up to December 31, 2024 [4].